Kamal Nayyar, MD
Nephrology · Mineola, NYNPI 1679918742
Payments from drug & device makers
Across 213 payments — averaging $23.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Otsuka America Pharmaceutical, Inc.$656
- GSK$397
- Amgen$379
- Cvrx, Inc.$298
- Novartis$267
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,73896%
- Education$1794%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $1,233 |
| Otsuka America Pharmaceutical, Inc. | 28 | $656 |
| GSK | 22 | $397 |
| Amgen | 15 | $379 |
| Cvrx, Inc. | 2 | $298 |
| Novartis | 11 | $267 |
| Novo Nordisk | 11 | $231 |
| Merck | 16 | $209 |
| Lilly USA, LLC | 9 | $196 |
| Boston Scientific | 3 | $105 |
| Abbott | 5 | $102 |
| Kowa Pharmaceuticals America, Inc. | 6 | $77 |
| Optos, Inc. | 3 | $72 |
| Pfizer | 3 | $71 |
| Boehringer Ingelheim | 3 | $60 |
| Bayer | 2 | $59 |
| Hikma Pharmaceuticals USA | 3 | $57 |
| Dexcom, Inc. | 2 | $51 |
| Exact Sciences | 2 | $50 |
| Amarin Pharma, Inc. | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $41 |
| Shield Therapeutics Inc | 2 | $38 |
| Sanofi | 1 | $33 |
| Vifor Pharma, Inc. | 1 | $30 |
| Johnson & Johnson | 2 | $30 |
| Baxter Healthcare | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Travere Therapeutics, Inc. | 1 | $22 |
| Heartflow, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Calliditas Therapeutics US Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$364
- BREZTRI$364
- AIRSUPRA$364
- Barostim Neo System$298
How this compares
$4,917 in reported general payments places this provider in the 75th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 148 | $142,096 |
| MounjaroTirzepatide | 52 | $55,433 |
| FarxigaDapagliflozin Propanediol | 34 | $45,058 |
| JanuviaSitagliptin Phosphate | 23 | $33,512 |
| EliquisApixaban | 17 | $17,296 |
| VeltassaPatiromer Calcium Sorbitex | 14 | $14,894 |
| Repatha SureclickEvolocumab | 21 | $13,884 |
| LivaloPitavastatin Calcium | 17 | $11,124 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,194 |
| Rosuvastatin Calcium | 79 | $3,783 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $3,410 |
| Atorvastatin Calcium | 388 | $2,886 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 87 | $2,127 |
| Metoprolol Succinate | 138 | $1,861 |
| Pregabalin | 28 | $1,829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $231 | $142,096148 claims |
| Lilly USA, LLCMounjaro | $196 | $55,43352 claims |
| AstraZenecaFarxiga | $1,233 | $45,05834 claims |
| MerckJanuvia | $209 | $33,51223 claims |
| PfizerEliquis | $71 | $17,29617 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $77 | $11,12417 claims |
| GSKBreo Ellipta | $397 | $6,19413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 nephrology providers in New York.
Other nephrology in Mineola
- Steven FishbaneMineola$1M
- Naveed MasaniMineola$715K
- Binny KoshyMineola$170K
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
- David BernardNew York$6M
- Andrew BombackNew York$3.4M
- Pietro CanettaNew York$3.2M
- Robert LynnBronx$2M
- Jodumutt BhatMaspeth$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.